

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Fig. 1 (A)





Fig. 1 (B)



~53kDa spot is increased MCF-7/AR





Fig. 3 (A)

CEM




Fig. 3 (B)

CEM/VLB




Fig. 4 (A)




Fig. 4 (B) Streptavidin purified extracts




Fig. 4 (C)




Fig. 4 (D)




Fig. 5 A

Total biotinylated extract




Fig. 5 B

Streptavidin purified proteins




Fig. 5 C





Fig. 5 D MCF7 MCF7/AR






Fig. 6




Fig. 7




Fig. 8




Fig. 9

APPLICANT: E. Georges, et al.
APPLN. NO.: TBA
FILING DATE: December 15, 2003
TITLE: Vimentin Directed Diagnostics and
Therapeutics for Multidrug Resistant Neoplastic
Disease
DOCKET No.: 112418.147 (AUR-013US)
10 of 21




Fig.10




Fig. 11

FIGURE 12

A

POLYPEPTIDE SEQUENCE OF HUMAN VIMENTIN (GENBANK ACCESSION NO. P08670 (SEQ ID NO.))

```
1 MSTRSVSSSS YRRMFGGPGT ASRPSSRSY VTTSTRYSL GSALRPSTSR SLYASSPGGV
61 YATRSSAVRL RSSVPGVRL QDSVDFSLAD AINTEFKNTR TNEKVELQEL NDRFANYIDK
121 VRFLEQQNKI LLAELEQLKG QGKSRLGDLV EEMRELRRQ VDQLTNDKAR VEVERDNLAE
181 DIMRLREKLQ EEMLQREEAE NTLQSFRQDV DNASLARLDL ERKVESLQEE IAFLKKLHEE
241 EIQELOAQIQ EQHVQIDVDV SKPDLTAALR DVRQQYESVA AKNLQEAEWW YKSKFADLSE
301 AANRNNDALR QAKQESTEYR RQVQLTCEV DALKGTNESL ERQMREMEEN FAVEAANYQD
361 TIGRLQDEIQ NMKEEMARHL REYQDLLNVK MALDIEIATY RKLLEGEESR ISLPLPNFSS
421 LNLRETNLDS LPLVDTHSKR TFLIKTVETR DGQVINETSQ HHDDLE
```

B

NUCLEIC ACID SEQUENCE OF HUMAN VIMENTIN (GENBANK ACCESSION NO. X56134 (SEQ ID NO.))

```
1 CGGCCACCG CCGCCGCCCA GGCCATCGCC ACCCTCCGCA GCCATGTCCA CCAGGTCCGT
61 GTCCTCGTCC TCCTACCGCA GGATGTTCGG CGGCCCGGGC ACCGCGAGCC GGCCGAGCTC
121 CAGCCGGAGC TACGTGACTA CGTCCACCCG CACCTACAGC CTGGGCAGCG CGCTGCGCCC
181 CAGCACCAAGC CGCAGCCTCT ACGCCTCGTC CCCGGCGGGC GTGTATGCCA CGCGCTCCTC
241 TGCCGTGCGC CTGCGGAGCA GCGTGCCCGG GGTGCGGCTC CTGCAGGACT CGGTGGACTT
```

301 CTCGCTGGCC GACGCCATCA ACACCGAGTT CAAGAACACC CGCACCAACG AGAAGGTGGA
361 GCTGCAGGAG CTGAATGACC GCTTCGCCAA CTACATCGAC AAGGTGCGCT TCCTGGAGCA
421 GCAGAATAAG ATCCTGCTGG CCGAGCTCGA GCAGCTCAAG GGCCAAGGCA AGTCGCGCCT
481 GGGGGACCTC TACGAGGAGG AGATGCGGG A GCTGCGCCGG CAGGTGGACC AGCTAACCAA
541 CGACAAAGCC CGCGTCGAGG TGGAGCGCGA CAACCTGGCC GAGGACATCA TGCGCCTCCG
601 GGAGAAATTG CAGGAGGAGA TGCTTCAGAG AGAGGAAGCC GAAAACACCC TGCAATCTT
661 CAGACAGGAT GTTGACAATG CGTCTCTGGC ACGTCTTGAC CTTGAACGCA AAGTGGAATC
721 TTTGCAAGAA GAGATTGCCT TTTTGAAGAA ACTCCACGAA GAGGAAATCC AGGAGCTGCA
781 GGCTCAGATT CAGGAACAGC ATGTCCAAAT CGATGTGGAT GTTTCCAAGC CTGACCTCAC
841 GGCTGCCCTG CGTGACGTAC GTCAGCAATA TGAAAGTGTG GCTGCCAAGA ACCTGCAGGA
901 GGCAGAAGAA TGGTACAAAT CCAAGTTGC TGACCTCTCT GAGGCTGCCA ACCGGAACAA
961 TGACGCCCTG CGCCAGGCAA AGCAGGAGTC CACTGAGTAC CGGAGACAGG TGCAAGTCCCT
1021 CACCTGTGAA GTGGATGCC TAAAGGAAC CAATGAGTCC CTGGAACGCC AGATGCGTGA
1081 AATGGAAGAG AACTTGCCG TTGAAGCTGC TAACTACCAA GACACTATTG GCCGCCCTGCA
1141 GGATGAGATT CAGAATATGA AGGAGGAAAT GGCTCGTCAC CTTCGTGAAT ACCAAGACCT
1201 GCTCAATGTT AAGATGCC TTGACATTGA GATTGCCACC TACAGGAAGC TGCTGGAAGG
1261 CGAGGAGAGC AGGATTCTC TGCCCTTCC AAACTTTCC TCCCTGAACC TGAGGGAAAC
1321 TAATCTGGAT TCACTCCCTC TGTTGATAC CCACTAAAA AGGACACTTC TGATTAAGAC
1381 GGTGAAACT AGAGATGGAC AGGTTATCAA CGAAACTTCT CAGCATCACG ATGACCTTGA
1441 ATAAAAATTG CACACACTCA GTGCAGCAAT ATATTACAG CAAGAATAAA AAAGAAATCC
1501 ATATCTTAAA GAAACAGCTT TCAAGTGCCT TTCTGCAGTT TTTCAGGAGC GCAAGATAGA
1561 TTTGGAATAG GAATAAGCTC TAGTTCTAA CAACCGACAC TCCTACAAGA TTTAGAAAAAA
1621 AGTTTACAAC ATAATCTAGT TTACAGAAAA ATCTTGTGCT AGAATACTTT TTAAAAGGTA
1681 TTTGGAATAC CATTAAAAGT GCTTTTTTT TTCCAGCAAG TATCCAACCA ACTTGGTTCT
1741 GCTTCAATAA ATCTTTGGAA AACTA

Figure 13A : Procedure for immunofluorescence (non-permeabilized cells)




Figure 13B: Procedure for immunofluorescence (permeabilized cells)






Figure 14



MCF-7

MCF-7/AR

Figure 15



LS-11-15-03

Figure 16





Figure 17

17A

Expt	MDA/mito (epitopes)	Kd (nM)	r2
1	2764751	10.4	0.95
2	3477797	5.9	0.97
3	1496035	2.5	0.98
4	2720065	3.2	0.97
5	2012848	6.7	0.97
Ave	2494299	5.7	
Std	761530	3.1	

17B




Concentration [^{125}I]- α -Vimentin (nM)

17C

cells	AVE	STD	Kd	R/S
MCF-7	9.1.E+03	8.8.E+03	nd	41.2
MCF-7/AR	3.8.E+05	1.1.E+05	nd	
MDA	6.3.E+05	1.6.E+05	9.3 ± 2.8	
MDA/mito	2.5.E+06	7.6.E+05	5.7 ± 3.1	4.0
SKOV3	7.4.E+05	3.7.E+05	nd	
SKOV/T320	1.2.E+06	2.0.E+05	nd	
2008	4.1.E+04	2.2.E+04	nd	1.6
2008/T320	8.3.E+04	1.3.E+04	nd	2.0

Figure 18



LS-11-16-03

Figure 19

